Evidence map›Paper›PMID 37563252›Full record

ArticleScientific reports2023

Efficacy of microbicidal actives and formulations for inactivation of Lassa virus in suspension.

Todd A Cutts, Raymond W Nims, Joseph R Rubino, Julie McKinney, Jens H Kuhn, M Khalid Ijaz

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Validation of Marburg Virus Inactivation by AVL Buffer.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Todd A CuttsApplied Biosafety Research Program, Public Health Agency of Canada, 1015 Arlington St., Winnipeg, MB, R3E 3P6, Canada.
Raymond W NimsSyner-G Biopharma, 6000 Spine Road, Suite 201, Boulder, CO, 80301, USA.
Joseph R RubinoGlobal Research and Development for Lysol and Dettol, Reckitt Benckiser LLC, One Philips Parkway, Montvale, NJ, 07645, USA.
Julie McKinneyGlobal Research and Development for Lysol and Dettol, Reckitt Benckiser LLC, One Philips Parkway, Montvale, NJ, 07645, USA.
Jens H KuhnIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, B-8200 Research Plaza, Fort Detrick, Frederick, MD, 21702, USA.
M Khalid IjazGlobal Research and Development for Lysol and Dettol, Reckitt Benckiser LLC, One Philips Parkway, Montvale, NJ, 07645, USA. khalid.ijaz@reckitt.com.
Philips (United States) · USArray BioPharma (United States) · USNational Institutes of Health · USPublic Health Agency of Canada · CAReckitt Benckiser (United States) · US

Funding

NIAID NIH HHS HHSN272201800013C
6 · The paper itself

Abstract

The World Health Organization's R&D Blueprint list of priority diseases for 2022 includes Lassa fever, signifying the need for research and development in emergency contexts. This disease is caused by the arenavirus Lassa virus (LASV). Being an enveloped virus, LASV should be susceptible to a variety of microbicidal actives, although empirical data to support this expectation are needed. We evaluated the virucidal efficacy of sodium hypochlorite, ethanol, a formulated dual quaternary ammonium compound, an accelerated hydrogen peroxide formulation, and a p-chloro-m-xylenol formulation, per ASTM E1052-20, against LASV engineered to express green fluorescent protein (GFP). A 10-μL volume of virus in tripartite soil (bovine serum albumin, tryptone, and mucin) was combined with 50 μL of disinfectant in suspension for 0.5, 1, 5, or 10 min at 20-25 °C. Neutralized test mixtures were quantified by GFP expression to determine log

Indexed as

Anti-Infective AgentsDisinfectantsLassa FeverAnimalsChlorocebus aethiopsGreen Fluorescent ProteinsHumansLassa virusVero CellsAnti-Infective AgentsDisinfectantsGreen Fluorescent Proteins

Identifiers

PMID37563252
PMCPMC10415271
OpenAlexW4385724147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.